Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2023)

Historic EBIT Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' EBIT Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063875218800.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • Latest data reveals that Inhibikase Therapeutics reported EBIT Margin of 440356600.0% as of Q4 2023, which was down 4403497803600.0% from 5993.38% recorded in Q3 2023.
  • Inhibikase Therapeutics' EBIT Margin's 5-year high stood at 186.56% during Q1 2021, with a 5-year trough of 440356600.0% in Q4 2023.
  • In the last 4 years, Inhibikase Therapeutics' EBIT Margin had a median value of 5660.72% in 2023 and averaged 27549298.5%.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 2000000000bps in 2022, then plummeted by 2000000000bps in 2023.
  • Inhibikase Therapeutics' EBIT Margin (Quarter) stood at 704.66% in 2020, then crashed by -36703bps to 259334.41% in 2021, then soared by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Its EBIT Margin was 440356600.0% in Q4 2023, compared to 5993.38% in Q3 2023 and 5328.07% in Q2 2023.